Evaxion to Announce Q2 2025 Financial Results and Business Update on August 14, 2025.

Evaxion A/S will announce its Q2 2025 financial results and business update on August 14, 2025, before Nasdaq CM opens. The company's executive management will host a conference call and webcast at 14:30 CET/08:30 EST. Registration is required for dial-in details and a PIN code. The webcast recording will be available on the Evaxion website. Evaxion continues to drive innovation in vaccine development using its AI-Immunology platform.

Evaxion A/S (NASDAQ: EVAX), a pioneering clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday, August 14, 2025, before the Nasdaq CM opens. The company's executive management will host a conference call and webcast at 14:30 CET/08:30 EST. This event is free and open to the public, with registration required to receive dial-in details and a unique PIN code. The webcast recording will be available on the Evaxion website shortly after the event.

Evaxion's AI-Immunology™ platform leverages artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline targeting high unmet medical needs. Evaxion's commitment to transforming patients' lives through innovative and targeted treatment options underscores its mission.

The announcement will provide investors and stakeholders with insights into Evaxion's financial performance and strategic progress. The company's forward-looking statements, included in the announcement, highlight potential risks and uncertainties related to financial condition, development work, product development activities, market acceptance, and regulatory compliance [1][2].

Evaxion's AI-Immunology™ technology is part of a growing trend in the cancer vaccines market, which is expected to show remarkable growth trends from 2024 to 2034 [3]. The market is driven by advancements in personalized medicine and the increasing incidence of cancer. Companies like Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, and Merck are among the key players in this market, with Evaxion contributing to its innovation and development.

Investors are encouraged to tune in to the conference call and webcast to gain a comprehensive understanding of Evaxion's progress and financial performance. The event will also provide an opportunity for investors to ask questions and engage with the executive management team.

References:
[1] https://www.nasdaq.com/press-release/evaxion-announce-business-update-and-second-quarter-2025-financial-results-august-14
[2] https://www.globenewswire.com/news-release/2025/08/11/3130869/0/en/Evaxion-to-announce-business-update-and-second-quarter-2025-financial-results-on-August-14-2025.html
[3] https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/33964798/cancer-vaccines-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-dendreon-pharma-candel-therapeutics-glaxosmithkline-merck-aduro-biotech-astrazeneca-plc-dendreon/